QLife Holding
Qlife Holding AB is a Swedish diagnostics company built around the Egoo platform for decentralized biomarker testing. Through its subsidiary Egoo Health ApS, the group develops and commercializes home-use and point-of-care tests, devices, and consumables for blood-based health monitoring.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueAnalyzer hardware used to run decentralized blood tests.
Single-use cartridges and consumables used with the Egoo system.
Validation work and product development supporting market approval.
Ancillary services tied to product deployment and customer use.
Customers
Qlife sells to users and partners in decentralized diagnostics, including consumers managing chronic conditions, healthcare providers, and commercial partners evaluating the platform. The company also engages with IVD, pharmaceutical, and consumer health companies that may use the technology for collaboration, distribution, or commercialization.
Buy Egoo tests for convenient biomarker monitoring outside traditional labs.
Offer in-store blood testing and related consumables to drive repeat usage.
Use decentralized testing to support remote monitoring and care pathways.
IVD, pharma, and consumer health companies evaluate the platform for partnerships.
Strategy
Qlife is focused on commercializing decentralized diagnostics through the Egoo platform, with emphasis on regulatory milestones, product validation, and partner-led market access. The company is also pursuing pharmacy-based testing and strategic partnerships to broaden distribution and support recurring use of its consumables.
Clinical and regulatory clearance is required before broad commercialization.
Partners can accelerate distribution, credibility, and market reach.
Retail testing can increase access and testing frequency.
Test capsules can create repeat revenue tied to platform usage.
Geography
Qlife is headquartered in Göteborg, Sweden, and reports through a Swedish parent company with Danish subsidiary Egoo Health ApS. Its commercial focus has included Scandinavia and the UK, with additional activity and partner discussions referenced in China and other international markets.
Risks
Qlife’s business depends on successful clinical validation, regulatory approvals, and partner execution before products can scale commercially. As a development-stage diagnostics company, it also faces financing, dilution, manufacturing, and market-adoption risks typical of regulated medtech businesses.
- Regulatory approval delaysImpact: HighLikelihood: High
Products cannot be broadly marketed until validations and approvals are obtained.
Exposure: Egoo tests and new biomarker launches
- Financing and dilution riskImpact: HighLikelihood: Medium
The business is capital intensive and may need additional funding to continue development.
Exposure - Partner and commercialization riskImpact: MediumLikelihood: Medium
Market access depends on third-party partners and channel execution.
Exposure: Hipro partnership and pharmacy rollout
- Manufacturing and purchasing riskImpact: Medium
Diagnostic products require reliable production of devices and consumables.
Exposure - Intellectual property and competitionImpact: Medium
Competing diagnostics platforms and IP disputes can limit adoption and pricing power.
Exposure: Home diagnostics and biomarker testing
Accounting
Judgemental itemsRevenue is tied to transfer of control for devices and consumables, so shipment timing matters.
Impact: Quarterly revenue can fluctuate materially on small volumes
Internally generated intangible assets depend on technical feasibility and future benefit assumptions.
Impact: Affects operating expenses, assets, and future amortization
Development assets not yet in use are tested for impairment annually or when indicators arise.
Impact: Can create non-cash write-downs if commercialization assumptions weaken
Right-of-use assets and lease liabilities affect reported leverage and depreciation.
Impact: Changes balance-sheet presentation and operating cost profile
Similar listed companies
Publicly listed companies with a comparable business focus.
Boule Diagnostics
BOUL · Health Care
Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics.
Qiagen N.V
QGEN · Biological Products, (No Diagnostic Substances)
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Vitrolife
VITR · Health Care
Vitrolife Group is a global provider of medical devices and genetic testing solutions focused on reproductive health.
Swedish Orphan Biovitrum
SOBI · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Last updated: 24/09/2026